Evaluation of SLC6A2 and CYP2D6 polymorphisms’ effects on atomoxetine treatment in attention deficit and hyperactivity disorder

CONCLUSIONS: The findings of this study suggest that genotypes of polymorphisms within the SLC6A2 and CYP2D6 may play an influential role in treatment response or the severity of side effects associated with ATX in ADHD patients.

via https://pubmed.ncbi.nlm.nih.gov/39158690/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20240904010906&v=2.18.0.post9+e462414